Active	Status	Sponsor type	Region	Phase	Filter
10 Active 4 Inactive 14 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Abruzzese, Elisabetta
CRU3, NCT03505554: A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma	Recruiting	2	12	Europe	Lorlatinib, PF-06463922	University of Milano Bicocca, Pfizer	Anaplastic Large Cell Lymphoma, ALK-Positive	12/24	12/24
NCT02629692 / 2016-001754-18: Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies	Active, not recruiting	1/2	122	Europe, US, RoW	Vodobatinib (K0706) capsules	Sun Pharma Advanced Research Company Limited	Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)	08/26	08/26